Compared with negative cases, MEC patients with MAML2 gene rearrangement tend to exhibit more favorable clinicopathological features, including younger age at diagnosis, smaller tumor size, lower frequency of lymph node metastasis, lower clinical stage and histological grade, and longer overall and disease-free survival (5). The gene discussed is MAML2; the disease is neoplasm.